Men's Health Women's Health Senior's Health Antioxidants Sports Nutrition Diet & Weight Loss Vitamins & Minerals Herbs Specialty Supplements Targeted Supplements Spa Products Anti-Aging Basics Body Systems Body Structure Book Store Pet Health My Recommendation My Favorite Articles Our Most Popular Specials Bargain Basement Brands

MSM

Health News Archive 127 - Kidney Disease
<<back to structure/function index

81% Positive Response to Coenzyme Q10 Treatment for Chronic Kidney Failure

Ninety-seven patients (mean age, 48 years) with chronic renal failure (serum creatinine > 5 mg/dl), with a history of declining renal function for at least 12 weeks, were randomly assigned to receive, in double-blind fashion, water-soluble coenzyme Q10 (CoQ10; 60 mg, 3 times per day orally) or placebo for 12 weeks.

The 45 patients who were receiving hemodialysis at the start of the study were encouraged to decrease the frequency or stop dialysis if there was an increase in urine output and a decrease in serum creatinine of more than 2 mg/dl. In the patients receiving hemodialysis and CoQ10, the mean serum creatinine concentration decreased from 9.5 to 6.7 mg/dl; mean BUN decreased from 88.2 to 79.8 mg/dl; mean creatinine clearance increased from 40 to 54.9 ml/min; and 24-hour urine output increased from 1,300 to 1,920 ml. Renal function tended to worsen in hemodialysis patients receiving placebo, and the differences in the changes between groups were significant (p < 0.01 to p < 0.001).

Significant improvements in each of these parameters relative to the placebo group were also seen in the non-dialysis patients treated with CoQ10. The number of patients receiving dialysis decreased from 21 to 12 in the CoQ10 group, and remained unchanged at 24 in the placebo group (p < 0.02). Eighty-one percent of the patients receiving CoQ10 had a positive response to treatment.

Comment by Alan R. Gaby MD:

These results suggest that hydrosoluble CoenzymeQ10 (Q-Gel) can improve renal function and reduce the need for dialysis in patients with chronic renal failure. The public-health implications of this study are enormous, considering that chronic renal failure is a serious and debilitating disease and that the annual cost of dialysis in the United States is more than $22 billion.

According Dr. Singh, the lead author of this study (Interview with Kirk Hamilton; Clinical Pearls News, August, 2001, pp. 128-9), CoQ10 is usually effective if pre-treatment urine output, with or without furosemide, is at least 1,000 ml/day. However, if urine output is less than 500 ml/day, then CoQ10 usually does not work, presumably because the kidney has been irreversibly damaged.

Dr. Singh recommends that all patients with renal failure take 180 mg/day of water-soluble CoQ10 (Q-Gel) if their urine output is greater than 500 ml/day on dialysis. If urine output increases to 1,000 ml/day within 12 weeks, then CoQ10 is likely to be effective. Patients should be able to stop dialysis within 12-48 weeks if the urine output goes above 1,500 ml/day. If urine output does not increase in 12 weeks, then CoQ10 is unlikely to be effective.

While the mechanism by which CoQ10 improves renal function is not clear, it may work by improving cellular bioenergetics. Large controlled trials are urgently needed.

Source

Singh RB, et al. Randomized, double-blind, placebo-controlled trial of coenzyme CoQ10 in patients with end-stage renal failure. J Nutr Environ Med 2003;13:13-22.

Reprinted with exclusive permission of TOWNSEND LETTER for DOCTORS and PATIENTS - OCTOBER 2005